Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22377898 | 1.00 | KDM4E (0.34) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22378410 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22378741 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22377652 | 0.94 | ATM (0.38) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22379819 | 0.93 | DHFR (0.32) | — | |
| SCHEMBL22379242 | 0.93 | DHFR (0.32) | — | |
| SCHEMBL22152676 | 0.92 | KDM4E (0.35) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22154159 | 0.92 | KDM4E (0.35) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22153471 | 0.91 | KDM4E (0.34) | KDM4EATML3MBTL1SMN1; SMN2HIF1A | |
| SCHEMBL22379326 | 0.91 | KDM4E (0.37) | KDM4EATML3MBTL1SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CRY2 | KDM4E 3290/4885ATM 3429/4885L3MBTL1 1164/4885 |
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CYP1A1, CRY2 | KDM4E 3290/4885ATM 3429/4885L3MBTL1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.